• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A process for producing a bio-ink for additive deposition, in which a first solution comprising between 5% and 40% by weight of gelatin is supplied, a second solution comprising between 15% and 35% by weight of alginate, third solution comprising between 1% and 15% by weight of fibrinogen, and optionally living cells in suspension; and creating a mixture comprising: about 35% to 65% by volume of the first solution; about 15% to 35% by volume of the second solution; about 15% to 35% by volume of the third solution; these proportions being chosen so as to add up to 100%. This bio-ink allows the additive deposition of objects that can be polymerized with a solution comprising calcium ions and thrombin. These objects can be incubated and can be used as a substitute for body tissue, for example (with incorporated fibroblasts) as a skin substitute
    公开号:FR3046421A1
    申请号:FR1651797
    申请日:2016-03-03
    公开日:2017-07-07
    发明作者:Christophe Marquette；Lea Pourchet；Amelie Thepot；Santos Morgan Dos
    申请人:Lab Skin Creations；Centre National de la Recherche Scientifique CNRS；Universite Claude Bernard Lyon 1 UCBL；Institut National des Sciences Appliquees de Lyon ；Ecole Superieure de Chimie Physique Electronique de Lyon；
    IPC主号:
    专利说明:

    TECHNICAL FIELD The invention relates to the field of biotechnology, and more particularly that of cutaneous substitutes. BACKGROUND OF THE INVENTION It relates in particular to the manufacture of cutaneous substitutes intended for carrying out tests of pharmaceutical or cosmetic active principles.
    STATE OF THE ART
    In Europe cosmetic chemicals should no longer be tested in laboratory animals; we are therefore constantly trying to improve skin substitutes, to give them characteristics closer to those of a natural dermis, to reduce their cost of production and use. Among the different experimental methods for manufacturing biotechnological materials and matrices, it is the additive deposit methods that have received a lot of attention in recent years.
    Initially designed for the production of models of industrial plastic parts (rapid prototyping, see FR 2 567 668), the additive manufacturing methods, some of which are known under the terms "stereolithography" or "3D printing", have since ten of years explored in many fields of application. They generally comprise the deposition of a powdery, pasty or liquid phase (called "ink") in a controlled three-dimensional form on an initial substrate, followed by the solidification of this deposited phase, so as to obtain a three-dimensional shaped object. controlled. Said deposition is most often in several passes, each leading to the deposition of a powdery, pasty or liquid phase of controlled three-dimensional shape; these deposits are typically solidified passes by pass (stratum per stratum). Said powdery, pasty or liquid phase may be homogeneous (for example a homogeneous powder or a molten thermoplastic polymer wire) or may comprise a dispersion of solid particles in a liquid phase. Its viscosity can be a critical parameter, because the preform obtained after its deposition must not collapse waiting for its solidification (this waiting can be a fraction of a second). Its solidification can be achieved by very different techniques depending on the composition of the ink; it can also take place spontaneously, in particular in the case of a melt-extruded polymer which solidifies, or in the case of thixotropic pastes, or in the case of a polymer whose composition comprises molecules which react with each other (as described in US 6,942,830). For example, plastic parts can be made by depositing a polymerizable ink with the light (or heat generated by the absorption) of a laser beam, and metal parts can be made by depositing pastes. charged with metal particles or powders which are consolidated (usually by intermediate fusion) under the effect of a laser beam (technique known by the acronym SLS, "Selective Laser Sintering"); it is also possible to directly deposit molten metals. Thus one can manufacture industrial parts of complex shape. A multiplicity of techniques (and abbreviations) on the market, such as FDM ™ ("Fused Deposition Modeling"), multiple jet modeling, FTI (Film Transfer Imaging). The SFF (Solid Freeform Fabrication) acronym is used to denote a set of techniques capable of fabricating three-dimensional structures directly from Computer-Aided Design (CAS) files by additive techniques. The state of the art describes the implementation of additive manufacturing techniques in the field of biotechnology; three-dimensional structures based on so-called biological materials have thus been printed. More specifically, it is in this case inks based on biocompatible materials capable of being solidified. These materials can serve as a support ("scaffold" in English) for living cells that are introduced after the solidification of the support. Live cells can also be introduced directly into the ink, which is then a suspension comprising living cells; these inks are sometimes called "bioencres".
    This solidification can be done by photochemical means. By way of example, the document US 2014/0052285 describes the use of several types of light-curing hydrogels, namely PED-DA (= polyethylene glycol diacrylate), PEG-DA-PEA (poly-amide ester), GMA -chitosan and alginate, to make supports likely to be colonized by living cells. US 2013/0304233 discloses the manufacture of resorbable support structures based on PPF (polypropylene fumarate). US 7,780,897 and US Pat. No. 8,197,743 describe other embodiments of stereolithography using polyethylene glycol hydrogels solidified by a photochemical reaction. Photochemical solidification, however, requires photocatalysts, photoinitiators and / or dyes, in significant amounts (for example: 2% photoinitiator); these additives can pose a toxicological problem. Regarding the photocatalyst, even if the latter is not toxic as such, free radical production always promotes cell death, and may disturb the product obtained. For this reason, we are looking for an alternative to light curing for biotechnological applications.
    Hydrogels have also been used as a solidifiable pasty medium; US 7,051,654 describes a vast list. US 2014/003932 discloses photocurable hydrogels based on methyl acrylate. US 2014/0012407 more specifically describes thermoreversible hydrogels. EP 2 670 669 A1 discloses a method in which a suspension of living cells is deposited comprising a first hydrogel precursor capable of solidifying when the temperature falls below a critical gelation temperature, and a second precursor of crosslinkable hydrogel, solidifies the suspension deposited by cooling, and a crosslinking agent is added. The second precursor may be an alginate, hyaluronic acid, a cellulose derivative, chitosan, xanthan, fibrin, a pectin gel, polyvinyl alcohol. In general, the solidified hydrogels for cell culture support are known to those skilled in the art under the term "lattice". Other solidifiable systems are described in US 2013/0164339 and US 2014/00998709.
    Also known are alginate-based inks which are solidified with a solution to make supports for cell culture; such systems and methods are described in US 8,639,484, US 8,691,974 and US 8,691,274. US 2013/0017564 discloses the deposition of hydroxyapatite to make three-dimensional structures to which osteoblast cells can attach. 3D printing has also been used in biotechnology to apply an ink with living cells on a support promoting the development of cell cultures. US 2009/0208466 and WO 2014/039427 describe 3D printing with collagen-based inks (which may comprise alginate) comprising human cells. US 2011/0250688 describes the deposition of smooth muscle cells suspended in a hydrogel by 3D printing on a biological or synthetic substrate. US 2012/0089238 describes the deposition on a porous substrate (scaffold) of four different types of cells by 3D printing, each deposited in suspension from a dedicated print head, to create a complex three-dimensional structure mimicking a tissue. WO 2013/040087 describes the manufacture of biocompatible "lattice" type structures manufactured by 3D printing on which living cells characteristic of a certain range of tissues are fixed: smooth muscle cells, dermal fibroblasts, endothelial cells, stellate cells (in English). hepatic stellate cells), hepatocytes, monocytes, macrophages. The publication "Multi-layered culture of human skin fibroblasts and keratinocytes through three-dimensional freeform manufacturing" by W. Lee et al., Published in Biomaterials 30 (2009), p. 1587-1595 describes the 3D printing deposition of cells on a type I collagen-based hydrogel lattice deposited in the same manner. This publication notably describes the manufacture of multilayer collagen structures in which certain layers incorporate fibroblasts or keratinocytes; after incubation of the cells they can serve as a skin model.
    The publication "On-Demand Three-Dimensional Freeform Fabrication of Multi-Layered Hydrophel Scaffolf With Fluidic Channels" by W. Lee et al., Published in 2010 in the journal Bitechnology and Bioengineering, Vol. 105 (6), p. 1178-1186 discloses a method of depositing a biomaterial from alternating layers of a collagen-based hydrogel and a gelatin solution; the hydrogel is cross-linked with sodium bicarbonate, while the gelatin solution solidifies by cooling during the deposition. The cells to be cultured are contained in the collagen hydrogel. Upon incubation the gelatin solution becomes liquid and is rinsed off; thus creating a structure comprising dense layers of collagen hydrogel which alternate with low density layers left by the departure of the gelatin. Although this biomaterial allows cell culture, it is not a skin substitute.
    The publication "Design and Manufacture of Human Skin by Three-Dimensional Bioprinting" by V. Lee et al., Published in Tissue Engineering Part C, 20 (6) (2014), p. 473-484, shows that multilayer systems obtained by manual assembly and by 3D printing evolve in a completely different way under cell culture conditions: systems created by 3D printing develop well and keep their shape, whereas manually assembled systems shrink like a skin of sorrow. At present the vast majority of 3D biotechnology printing achievements lead to products that can serve as models for scientific studies; a large variety of cells and organs can be mimicked in this way. These model systems can be used to characterize pharmaceutical active principles on high cell cultures and maintained under conditions close to intracorporeal conditions. The publication "Three-dimensional printing of Heel cells for cervical tumor in vitro model" by Y. Zhao et al., Published in the journal Biofabrication 6 (1914), doi: 10.1088 / 1758-5082 / 6/3/035001, provides an example. In contrast, and still in the field of human skin, therapeutic issues are enormous because many unmet need exist. Thus, document US 2014/0012225 describes a device that makes it possible to deposit, over large areas of the surface of the human body, solidifiable hydrogels comprising epidermal cells as artificial skin; this device was designed to treat burn victims.
    The present invention focuses on the field of epithelial substitutes, and in particular on epithelia substitutes intended for carrying out tests of pharmaceutical or cosmetic active principles. The inventors have found that the traditional methods for manufacturing skin substitutes take a long time, from two points of view: firstly they take a lot of handling time (expressed in man-hours), because the manufacture of skin substitutes is a complex process; then, the skin substitute can not be used as it is but must first age for several months (typically about six months) before it can be put in culture condition. The cultivation phase itself takes at least six to seven weeks. It is noted that the complex handling during manufacture involves a risk of contamination of crops.
    The techniques of manufacturing skin substitutes from a bio-ink can be automated easily, they have good reproducibility and thus make it possible to obtain a standardized product and are faster: the biomaterial is mixed with the cells on the day of the production to form the bio-ink, and the maturation of the dermis is done in ten to fifteen days.
    However, the result is not very good, because one does not obtain artificial dermis allowing the culture of a stratified epidermis on its surface, which can serve as realistic model of a natural skin. Indeed, the publication "Standardized 3D Bioprinting ofSoft Tissue Models with Human Primary Cells" by M. Riemann et al., Published in 20 in J. of Laboratory Automation, p. 1 - 14 (doi: 10.1177 / 2211068214567146) describes the manufacture of a skin substitute by additive deposition of successive layers (individual thickness: 0.05 mm) of a photopolymerizable bio-ink; a matrix layer is alternated with a layer comprising fibroblasts. Each layer is immediately photopolymerized. The bio-ink is based on PEG. The skin substitute thus obtained, however, does not have the stratified structure of a natural epidermis, and it includes many holes.
    The problem of manufacturing, using additive techniques, a skin substitute that has a sufficient structural and functional similarity with the natural skin remains unresolved.
    Object of the invention
    According to the invention the problem has been solved by the use of a novel bio-ink composition, comprising a mixture of natural gelatin and alginate, which is solidified by three different means: during the deposition of the ink, the gelatin solidifies, which keeps the shape of the ink roll deposited. After deposition, the deposited object is treated with a solution comprising calcium and thrombin ions, in order to solidify the alginate with the calcium ions and to coagulate fibrinogen by the effect of thrombin.
    Thus, a first subject of the invention is a process for manufacturing a bio-ink for additive deposition, in which: (a) A first solution comprising between 5% and 40% by weight of gelatin (preferably between 6%) is supplied; % and 30% by weight) and between 0% and 5% by weight of NaCl; (b) supplying a second solution comprising between 1% and 12% by weight of alginate (preferably between 1% and 8% by weight) and between 0% and 5% of NaCl; (c) providing a third solution comprising between 1% and 15% by weight of fibrinogen (preferably between 3% and 15% by weight), and optionally living cells (such as fibroblasts) in suspension; (d) creating a mixture comprising: about 35% to 65% by volume of the first solution; about 15% to 35% by volume of the second solution; about 15% to 35% by volume of the third solution; these proportions being chosen so as to add to 100%, and in which process: the order of steps (a), (b) and (c) is indifferent, the NaCl content is chosen so that in said first solution and said second solution combined is between 0.2% and 5% by weight, preferably between 0.2 and 3% by weight, and even more preferably between 0.4% and 2% by weight.
    Said living cells may especially be selected from the group consisting of: adipocytes and preadipocytes, endothelial cells, nerve cells, dendritic dermal cells, Langerhans cells, melanocytes, Merkel cells, sebocytes, macrophages, mast cells, epithelial cells of hair follicles. Another object of the present invention is the bio-ink obtainable from this process. It may contain living cells, and especially fibroblasts. Gelatin gives this bio-ink a viscosity which has a transition point (gelling point) at a temperature typically between 27 ° C and 32 ° C, and preferably between 28 ° C and 30 ° C: the bio Ink is fluid above this temperature and gels below this temperature. This gelation takes place in particular when the bio-ink is brought to a temperature T1 greater than its gel point and deposited on a substrate at a temperature T2 below this gel point: in this case it can immediately solidify without its spread completely, possibly keeping the shape of the extrusion rod. Thus, the bio-ink can be used in additive deposition processes.
    Yet another object of the invention is a method of manufacturing a body tissue substitute, wherein: (i) supplying a bio-ink according to the invention; (ii) supplying an aqueous solution (called "polymerization solution") comprising between 1% and 5% by weight of calcium ions and between 5 U / ml and 40 U / ml (and preferably between 10 U / ml and 30 U / mL) thrombin; (iii) said bio-ink is brought to a temperature T1 greater than its gel point and is deposited on a substrate at a temperature T2 below the gel point of said bio-ink, where it gels to form an object of controlled three-dimensional shape called "raw printed object", (iv) treating said raw printed object with said polymerization solution to consolidate said raw printed object into a body tissue substitute; (v) optionally, in the case where said bio-ink comprises living cells, said body substitute precursor is incubated in a cell culture medium. This incubation is advantageously carried out at a temperature of between 36 ° C. and 38 ° C., preferably in a humid atmosphere with 5% CO 2.
    This method can be achieved by simple deposition or additive deposition, the additive deposition allowing the creation of raw printed objects having a certain controlled two-dimensional extension, or even objects having a controlled three-dimensional shape.
    Advantageously, T1 is between 28 ° C. and 37 ° C. (preferably between 28 ° C. and 33 ° C.) and T2 is between 0 ° C. and 20 ° C. (and preferably between 4 ° C. and 18 ° C. ). It is the treatment of the raw printed object with the polymerization solution which definitively consolidates it: if the coagulation of the alginate by the calcium can be at least partially reversible by the possible departure of the calcium, the coagulation of the fibrinogen by the Thrombin is irreversible. In the process according to the invention this consolidation is homogeneous in the thickness of the object.
    The treatment of said raw printed object with said polymerization solution may be carried out by dipping, preferably at a temperature T3 greater than T1 and preferably between 35 ° C and 38 ° C.
    According to a particular embodiment of the invention, said precursor of body tissue is a cutaneous precursor precursor. In this case, said bio-ink comprises living cells in suspension which are fibroblasts. Said incubation is carried out at a temperature between 36 ° C and 38 ° C in a humid atmosphere and 5% CO2. It advantageously comprises a first incubation phase of between one and forty days, and a second incubation phase of between five and forty days, knowing that between the first and the second phase is deposited on the surface of said skin substitute an aqueous suspension. of keratinocytes.
    Said skin substitute precursor may have a flat shape or the like. In one embodiment said raw printed object comprises a substantially flat upper surface and has a homogeneous distribution of fibroblasts, which is between 0.5 and 10 x 105 (and preferably between 1 and 5 x 105) fibroblasts per cm 2 of surface upper flat.
    Still for the purpose of preparing a skin substitute, the amount of keratinocytes deposited is advantageously between 0.5 and 10 × 10 5 (and preferably between 1 and 5 × 10 5) keratinocytes per cm 2 of flat upper surface.
    Yet another subject of the invention is a substitute for body tissue, and in particular a skin substitute, obtainable by the method according to the invention.
    The method according to the invention allows the manufacture of cutaneous substitutes comprising a dermal layer comprising fibroblasts, an epidermal layer, and a horny layer comprising keratinocytes and melanocytes. This structure is well stratified. The skin substitute according to the invention can be used to study the effect of cosmetic or dermatological active ingredients, or for toxicological studies.
    Description of figures
    Figures 1 to 3 illustrate certain aspects of the invention.
    Figure 1 shows schematically the method according to the invention.
    Figure 2 shows an optical micrograph of a cross-section through a skin substitute according to the invention. The black bar at the bottom right represents the length of 50 pm.
    Figure 3 shows an optical micrograph of a cross-section through a skin substitute according to the invention, with immunohistochemical staining of vimentin. The white bar at the bottom right represents the length of 50 pm.
    detailed description
    The present invention makes it possible to create equivalent dermal substitutes by means of 3D printing. This new manufacturing process saves time and ease of manufacture of dermal substitutes extremely advantageous, simple and reproducible. The manufacturing and maturation times are very short.
    The bio-ink is composed of a mixture of biomaterials capable of forming a hydrogel and cells. It can be prepared just before use from stable aqueous solutions. Once the solutions have been prepared with the right concentrations, it is sufficient to gently mix them with a suspension of cells (typically fibroblasts) in a syringe. Then the syringe is mounted on the bio-printer. Advantageously, a syringe pump is provided in order to have a flow control; for example, the syringe pump can be controlled by a worm and a motor that exerts a constant pressure on the liquid or gel to be extruded. Thus one prints a hydrogel object; this object is typically a flat object. Once the hydrogel is printed, it is necessary to immerse it in a biocompatible polymerization solution, which will allow the biomaterials to form a solid network and maintain the desired three-dimensional shape. Then, in a step also called "maturation step" the cells are allowed to grow. During this cellular development in three-dimensional network, the printed cells (fibroblasts) contained in the polymerized hydrogel secrete their extracellular matrix. The hydrogel will then gradually be resorbed to give way to the emergence of neosynthesized tissue where specific functions will appear, which is a clear advantage over a "scaffold" approach where biomaterials are sometimes resorbable. Seeding the surface with keratinocytes followed by appropriate incubation provides a stratified skin substitute comprising the dermis, the dermal-epidermal junction, the epidermis and the stratum corneum.
    For the implementation of the method according to the invention, the bio-ink must be prepared according to proportions and a predefined and precise order.
    In a first step, alginate and gelatin powders are supplied, sterilized and solubilized to obtain two stock solutions: the first is an aqueous gelatin solution obtained by dissolving gelatin powder (preferably at a concentration between 5% w / v and 40% w / v) in a solution of NaCl (preferably at a concentration of between 0.2% w / v and 5% w / v, more preferably between 0.4% w / v and 3% w / v, and even more preferably between 0.5% w / v and 1.4% w / v), the second is an aqueous solution of alginate, obtained by dissolving alginate powder (preferably so-called "Very Low Viscosity") at a concentration of between 1% w / v and 10% w / v (preferably between 2% w / v and 7% w / v) in a solution of NaCl (preferably at a concentration of concentration between 0.2% w / v and 5% w / v, more preferably between 0.4% w / v and 3% w / v, and even more preferably between 0.5% w / v and 1% w / v. , 4% w / v). Both solutions are stable and can be stored.
    Advantageously, the same NaCl solution is used to prepare these two solutions. The following concentration ranges are particularly advantageous: • Gelatin solution between 6% w / v and 30% w / v, alginate solution between 1% w / v and 8% w / v; NaCl solution between 0.2% w / v and 3% w / v (preferably between 0.4% w / v and 2% w / v, and even more preferably between 0.5% w / v and 1%, 4% w / v). • Gelatin solution between 10% w / v and 30% w / v, alginate solution between 2% w / v and 6% w / v; NaCl solution between 0.2% w / v and 3% w / v (preferably between 0.4% w / v and 2% w / v, and even more preferably between 0.5% w / v and 1%, 4% w / v). • Gelatin solution between 15% w / v and 26% w / v, alginate solution between 2% w / v and 6% w / v (and preferably between 3% w / v and 5% w / v) ; NaCl solution between 0.2% w / v and 3% w / v (preferably between 0.4% w / v and 2% w / v, and even more preferably between 0.5% w / v and 1%, 4% w / v). Gelatin solution between 17% w / v and 24% w / v, alginate solution between 2% w / v and 6% w / v (and preferably between 3% w / v and 5% w / v) ; NaCl solution between 0.4% w / v and 2% w / v (preferentially between 0.5% w / v and 1.4% w / v, and even more preferably between 0.6% w / v and 1% w / v). , 3% w / v).
    The alginate powder is a commercially available product, and the so-called "Low Viscosity" quality is preferred, and even more so the "Very Low Viscosity" quality.
    Furthermore, a third solution is prepared which is an aqueous solution of fibrinogen, preferably at a concentration of between 1% w / v and 15% w / v (more preferably between 3% w / v and 12% w / v, and even more preferably between 5% w / v and 10% w / v) in which an appropriate cell concentration (typically between 0.5 and 5 million cells / ml (preferably between 1 and 3.5 million per ml) has been introduced. For example, for a dermal precursor deposition test, 2 ml of this solution may be prepared, which cells are especially fibroblasts.
    In a third step, the bio-ink is prepared from these three solutions so as to obtain a mixture which contains about 35% to 65% (preferably about 45% to 55%, and still more preferably about 50%) of the mixture. first solution (gelatin), about 15% to 35% (preferably about 20% to 30%, and still more preferably about 25%) of the second solution (alginate) and about 15% to 35% (preferably about 20%) at 30%, and still more preferably about 25%) of the third solution for a total of 100%, these percentages being expressed in percent by volume.
    In a fourth step, a fourth aqueous solution is prepared, which is the polymerization solution. It comprises calcium in solution at about 1 to 5% w / v and preferably about 3% w / v, to which thrombin is added at a final concentration of about 20 U / ml. This polymerization solution must be supplied in sufficient quantity to allow to immerse the object obtained by 3D printing in order to obtain a polymerized gel in a homogeneous manner. This fourth step can be performed before or during the previous three steps, but the storage duration of this fourth solution is limited; the inventors have observed that when the fourth solution is prepared just before its use, a more homogeneous solidification and polymerization of the bio-ink is obtained.
    In a fifth step, the printing is carried out, that is to say the deposition of the ink on a support. For this purpose the ink is brought to a temperature T1 sufficient to melt the gelatin. This temperature T1 depends on the exact composition of the ink and must be determined by simple tests: for the domain the most preferred composition range indicated above a temperature T1 of the order of 28 ° C to 29 ° can suit. This printing can be carried out by any appropriate means, for example using a syringe mounted on a carriage, on which the syringe moves along an axis, and the carriage moves in a direction orthogonal to said axis. The substrate is placed on a table or platform. Displacement along the axis of the height can be provided either for the carrier carriage of the syringe or for the table or carrier platform of the substrate.
    The substrate is advantageously cooled so that the gelatin immediately solidifies; This temperature T2 of the substrate depends on the composition and temperature T1 of the ink and the speed of its deposition; it can be determined by simple tests. In another embodiment the printing assembly is in a cold room, that is to say at the temperature T2, optionally the syringe can be heated to the temperature T1. This embodiment is advantageous for allowing the manufacture of thicker structures or more complex shapes, for which the thermal conduction through the layer of ink that has just been deposited does not allow the ink layer in the process of deposit a sufficiently fast cooling.
    In a sixth step the raw printed object is consolidated by treating it with the polymerization solution (fourth solution), preferably by total immersion; thus we obtain an object called "solidified object". The contact time between the raw printed object and the polymerization solution is preferably at least fifteen minutes. During this step, the temperature T3 of the polymerization solution is preferably above the melting temperature of the gelatin. This allows the gelatin to pass into the aqueous phase, and thus most of the gelatin is removed from the solidified object. This produces an object called "cutaneous precursor precursor". The temperature T3 can be about 37 ° C.
    Steps 5 and 6 are schematically illustrated in FIG.
    In a sixth step, the skin substitute precursor is incubated to obtain a skin substitute. This incubation is done in three phases. During a first incubation phase, said cutaneous precursor precursor is immersed in a suitable fibroblast culture medium, preferably at a temperature of about 37 ° C. The duration of this incubation may be between three and twenty days (up to 40 days with keratinocytes); a duration of between eight and fifteen days is preferred; a duration of twelve days is optimal for fibroblasts. At the end of this first incubation phase, an aqueous suspension of keratinocytes is applied to the surface of the cutaneous precursor precursor. A concentration of between 1 and 5 × 10 5 cells per cm 2 is suitable.
    Then, during a second incubation phase, the skin replacement precursor is immersed in a suitable culture solution, for example Green's medium; it is necessary to bring nutrients regularly (every day preferably). This second incubation phase lasts between five and ten days, preferably about seven days. The temperature is 37 ° C.
    And finally, during a third incubation phase, the skin replacement precursors are maintained on the surface of the differentiation culture medium and incubated for a period of between 15 and 30 days, preferably between 18 and 25 days, typically 21 days. . The temperature is 37 ° C. Thus one obtains a cutaneous substitute. Said differentiation medium typically comprises DMEM as well as specific additives; in one advantageous embodiment, these additives are: hydrocortisone (0.4 μg / ml), insulin (5 μg / ml), bovine albumin (8 mg / ml).
    The bio-printing process according to the invention makes it possible to obtain objects of sizes centimetric or even decimetric. The printer looks like a classic FDM 3D printer (Fused Deposition Modeling) but the syringe driver then replaces the plastic extruders.
    The bio-ink according to the invention has three objectives:
    Maintaining the hydrogel with adequate rheology during the printing process (extrusion),
    The formation of a homogeneously polymerized object, which will keep its shape obtained in 3D,
    Allow the development of a cellular network in 3D.
    These three functions have been validated through the use of the following biomaterials. Gelatin, a collagen-based polymer with a phase transition temperature of 29 ° C, was used as a rheological component, which gives the bio-ink its hold once printed on a cooled substrate and which can then be removed in the subsequent steps of the process. Alginate, a carbohydrate-based polymer with the ability to form a hydrogel in the presence of calcium, used as a structural element, provides mechanical stability to the printed bio-ink once the solubilized gelatin. Fibrinogen, a glycoprotein with the ability to form a hydrogel under the action of thrombin, used both as a building block and maturation thanks to its cell adhesion components (RGD patterns). The invention has many applications. The method of manufacturing a body tissue substitute according to the invention makes it possible to manufacture body tissue substitutes of different natures. Indeed, one can incorporate in the bio-ink according to the invention all types of living cells. By way of example, all the other cell types of the skin (including: adipocytes and preadipocytes, endothelial cells, nerve cells, dendritic dermal cells, Langerhans cells, melanocytes, Merkel cells, sebocytes can be incorporated into the bio-ink. macrophage, mast cells, epithelial cells of hair follicles). The process makes it possible to manufacture substitutes for all the epithelia of the body (cornea, oral mucosa, esophagus, etc.) as well as cartilage substitutes.
    Thus, the body tissue substitute according to the invention can be used not only as a skin substitute for tests of cosmetic, pharmaceutical and chemical products, but also for clinical applications, for example in reconstructive and reconstructive surgery. For example, the skin substitute according to the invention can be used as skin for burns. The method of manufacturing a body tissue substitute by additive deposition according to the invention also makes it possible to manufacture objects of complex size, and thus it is possible to manufacture ear or nose substitutes for example.
    Examples
    Example 1: Cell Culture and Harvesting
    This example illustrates a method for amplifying and harvesting cells (fibroblasts and keratinocytes) which can then be used in the manufacture of the skin substitute according to the invention.
    Keratinocytes and dermal fibroblasts have been isolated from a human preputium.
    The keratinocytes were cultured on irradiated human fibroblasts according to a technique well known to those skilled in the art, using the culture medium known as "Green's medium" containing DMEM and Ham's F12 (in a ratio of 3: 1 ), adenine (24.3 μg / mL), human epidermal growth factor (10 ng / mL), hydrocortisone (0.4 μg / mL), insulin ( Humulin®, 5 μg / mL), 2 x 10'9 M tri-iodo-L-thyronine (5 μg / mL), 10'1 ° M isoproterenol, penicillin (100 U / mL), streptomycin ( 100 μg / mL) and 10% fetal calf serum. The keratinocytes harvested during passages 2, 3 and 4 were used.
    The fibroblasts were cultured in a suitable medium comprising DMEM, 20% newborn calf serum and antibiotics at 37 ° C in an atmosphere containing 5% CO 2. The fibroblasts harvested during passages 5, 6, 7 and 8 were used.
    Example 2 Deposit by Additive Technique (Process According to the Invention)
    A first aqueous gelatin solution was prepared by dissolving a 20% w / v gelatin powder in a 0.9% w / v NaCl solution. A second aqueous alginate solution was prepared by dissolving 4% w / v alginate powder (Very Low Viscosity) in 0.9% w / v NaCI solution. A third aqueous solution of fibrinogen at 8% w / v was prepared in which suspended fibroblasts (obtained according to Example 1) were introduced at a cell concentration of 2 million cells / ml.
    These three solutions were then mixed so as to obtain a mixture (called "bioencre") which contains 50 vol.% Of the first solution (gelatin), 25 vol.% Of the second solution (alginate) and 25 vol. the third solution (fibroblasts taken up in fibrinogen.
    An aqueous polymerization solution comprising 3% w / v calcium and thrombin was prepared at a final concentration of 20 U / mL.
    The bio-ink has a viscous transition at 29 ° C. It was heated to a temperature of about 30 ° C and used at this temperature for additive deposition according to a deposition technique of known type, through a syringe equipped with a syringe pump to be able to control the flow rate. The substrate was at a temperature of about 4 ° C, and thus the deposited ink solidified immediately. From a bead with a diameter of 300 .mu.m was deposited several layers with a total thickness of about 10 mm on a surface of the order of a few square centimeters. Flat objects were thus obtained which included a homogeneous distribution of fibroblasts at 2.5 x 105 fibroblasts per cm 2.
    Then each raw printed object thus deposited was soaked in the polymerization solution to crosslink the alginate and coagulate the fibrinogen maintained at a temperature of 37 ° C to polymerize the alginate and coagulate the fibrinogen. The flat object thus obtained is called here "cutaneous precursor precursor".
    Example 3 Maturation of the Skin Substitute Precursor (Process According to the Invention)
    The skin substitute precursors were incubated for 12 days in a fibroblast culture medium comprising 1 mM ascorbic acid 2-phosphate; they were fed each day. After twelve days keratinocyte cutaneous precursor precursors were applied to the surface at a concentration of 2.5 x 10 cells per cm 2.
    The skin substitute precursors were incubated for a first seven-day incubation period in Green medium immersion as described above, with a concentration of 1mM ascorbic acid 2-phosphate and antibiotics; they were fed each day.
    Then the skin substitute precursors were incubated for a second 21-day incubation period, maintained on the surface of the liquid, in a differentiation medium containing DMEM with hydrocortisone (0.4 μg / mL), insulin (5 μg / mL), ascorbic acid 2-phosphate and antibiotics; the differentiation medium included bovine serum albumin at 8 mg / mL.
    Cutaneous substitutes were thus obtained. They can be used to carry out tests of cosmetic or chemical products.
    Figure 2 shows a cross-section through such a skin substitute. We can see the epidermis having on its periphery a true stratum corneum, and including keratinocytes. The dermal-epidermal junction is clear. The dermis comprises fibroblasts (in Figure 2 we see only the nuclei, surrounded by a black line). In the dermis we perceive pores; these are folded progressively extracellular matrix secreted by the fibroblasts.
    Figure 3 shows the intermediate filaments of the fibroblast cytoskeleton in the dermis substitute (immunohistochemical labeling of vimentin). We note the three-dimensional shape of the cytoskeleton, which resembles that in a healthy natural dermis.
    Example 4
    This example combines attempts to manufacture dermal substitutes according to methods according to the state of the art or new processes, which are unsatisfactory.
    Example 4a: Photopolymerizable Ink Based on PEG Diacrylate
    A skin substitute precursor was prepared with a photopolymerizable PEG-DA (polyethylene glycol diacrylate) bio-ink using a method similar to that described in connection with the present invention. The photoinitiator was Irgacure ™ 819 (Bis (2,4,6-trimethylbenzoyl) -phenylphosphine oxide, CIBA company). After incubation, a 100% cell death rate was observed after 2 days. Without wishing to be bound by this theory, the inventors believe that it is not the photoinitiator as such that is cytotoxic but the free radicals whose generation it promotes.
    Example 4b: Ink according to the invention but without fibrinogen
    A skin substitute precursor according to the invention was prepared except that the bio-ink did not contain fibrinogen. In this case, despite good gel performance, the cells did not develop satisfactorily during the incubation due to the absence of a cell adhesion pattern within the gel
    Example 4c: Ink too fluid
    The method according to the invention was used, using different types of alginates which differed in particular in their viscosity: "Low Viscosity" and "High Viscosity" instead of "Very Low Viscosity". It has been found that with the ink "High Viscosity" one does not obtain a satisfactory extrusion. With the "Low Viscosity" ink the process can be set to obtain raw printed objects, but this embodiment is conducive to the instability of the extrusion, and is not preferred.
    Example 4d: Other causes of failures
    Failures (formation of a skin substitute precursor of poor morphology and / or quality) have been observed in the following cases:
    Short contact time between the bio-ink after its application and the polymerization solution (less than about fifteen minutes); Failure of total immersion of the bio-ink deposit during its polymerization; - Aging of the polymerization solution.
    Example 5: Manufacture of a total skin with the 3 layers of the skin: hypodermis, dermis and epidermis (process according to the invention).
    With the same method it is possible to print the three layers of the skin with three different syringes comprising the bioencre and different cells: a first syringe contains pre-adipocytes and / or mature adipocytes diluted in the bioencre. This hypodermis is printed in several layers. It is printed first to form the deepest layer of the skin. the second syringe contains the fibroblasts in the bioencre as described in the method. This part of the dermis is printed in several layers on the surface of the pre-printed hypodermis. The third syringe contains dilated keratinocytes in a slightly different bioencre. This epidermis is printed in one or more layers on the surface of the dermis layer. Melanocytes can be added at any time to the suspension of keratinocytes in a proportion of 1/10 to 1/2, to obtain pigmented skin.
    权利要求:
    Claims (10)
    [1" id="c-fr-0001]
    A process for producing a bio-ink for additive deposition, in which: (a) A first solution comprising between 5% and 40% by weight of gelatin (preferably between 6% and 30% by mass) and between 0 is supplied; % and 5% by weight of NaCl; (b) (supplying a second solution comprising between 1% and 12% by weight of alginate (preferably between 1% and 8% by weight) and between 0% and 5% of NaCl; (c) supplying a third solution comprising between 1% and 15% by mass of fibrinogen (preferably between 3% and 15% by weight), and optionally living cells in suspension, (d) creating a mixture comprising: approximately 35% to 65% by volume of the first solution; about 15% to 35% by volume of the second solution, about 15% to 35% by volume of the third solution, these proportions being chosen so as to add up to 100%, and in which process: the order of the steps (a) ), (b) and (c) is indifferent, the NaCl content is chosen so that in said first solution and said second solution combined it is between 0.2% and 5% by weight, preferably between 0, 2 and 3% by weight, and even more preferably between 0.4% and 2% by weight.
    [2" id="c-fr-0002]
    2. Bio-ink obtainable from the process according to claim 1.
    [3" id="c-fr-0003]
    A method of making a body tissue substitute, wherein: (i) supplying a bio-ink according to claim 2; (ii) supplying an aqueous solution (called "polymerization solution") comprising between 1% and 5% by weight of calcium ions and between 5 U / ml and 40 U / ml (and preferably between 10 U / ml and 30 U / mL) thrombin; (iii) said bio-ink is brought to a temperature T1 greater than its gel point and is deposited on a substrate at a temperature T2 below the gel point of said bio-ink, where it gels to form an object controlled three-dimensional shape called "raw printed object"; (iv) treating said raw printed object with said polymerization solution to consolidate said raw printed object into a body tissue substitute; (v) optionally, in the case where said bio-ink comprises living cells, said body substitute precursor is incubated in a cell culture medium.
    [4" id="c-fr-0004]
    4. The process according to claim 3, wherein T1 is between 27 ° C and 32 ° C and T2 is between 4 ° C and 20 ° C.
    [5" id="c-fr-0005]
    5. The method of claim 3 or 4, wherein the treatment of said printed object with said polymerization solution is performed by soaking at a temperature T3 greater than T1 and preferably between 35 ° C and 38 ° C.
    [6" id="c-fr-0006]
    The method of any of claims 3 to 5, wherein said body tissue precursor is a skin substitute precursor, and said bio-ink comprises living cells in suspension which are fibroblasts; o said incubation is carried out at a temperature between 36 ° C and 38 ° C and comprises a first incubation phase of between eight and forty days, and a second incubation phase between five and ten days, knowing that between the first and second phase is deposited on the surface of said skin substitute an aqueous suspension of keratinocytes.
    [7" id="c-fr-0007]
    The method of claim 6, wherein said raw printed object comprises a substantially flat upper surface and has a homogeneous distribution of fibroblasts, which is between 0.5 and 10 x 105 (and preferably between 1 and 5 x 105) fibroblasts per cm2 of flat upper surface.
    [8" id="c-fr-0008]
    8. The method of claim 7, wherein the amount of deposited keratinocytes is between 0.5 and 10 x 10 5 (and preferably between 1 and 5 x 10 5) keratinocytes per cm 2 of flat upper surface.
    [9" id="c-fr-0009]
    A body tissue substitute obtainable by the method of any one of claims 3 to 8.
    [10" id="c-fr-0010]
    A body tissue substitute according to claim 9, characterized in that it is a skin substitute comprising: a dermal layer comprising fibroblasts, an epidermal layer, and a stratum corneum comprising keratinocytes.
    类似技术:
    公开号 | 公开日 | 专利标题
    FR3046421A1|2017-07-07|PROCESS FOR MANUFACTURING SKIN SUBSTITUTES BY ADDITIVE DEPOSITION
    Cidonio et al.2019|The cell in the ink: Improving biofabrication by printing stem cells for skeletal regenerative medicine
    JP6712220B2|2020-06-17|Method for printing a tissue construct having an embedded vasculature
    Billiet et al.2012|A review of trends and limitations in hydrogel-rapid prototyping for tissue engineering
    Maher et al.2009|Construction of 3D biological matrices using rapid prototyping technology
    Moroni et al.2006|Polymer hollow fiber three-dimensional matrices with controllable cavity and shell thickness
    Shi et al.2015|3D printing scaffolds with hydrogel materials for biomedical applications
    WO2009064437A1|2009-05-22|Oriented protein films as a substrate for cell growth
    Park et al.2011|Fabrication of hydrogel scaffolds using rapid prototyping for soft tissue engineering
    US20200189182A1|2020-06-18|Cross-linkable microgel composite matrix bath for embedded bioprinting of perfusable tissue constructs
    Ramesh et al.2021|Extrusion bioprinting: Recent progress, challenges, and future opportunities
    Tabriz et al.2020|3D printed scaffolds for wound healing and tissue regeneration
    Pereira et al.2013|Biofabrication of hydrogel constructs
    Liew et al.2018|Laser-based fabrication of 3D hydrogel constructs using bessel beams
    Burke et al.2017|Bioprinting: uncovering the utility layer-by-layer
    Yadegari et al.2017|Specific considerations in scaffold design for oral tissue engineering
    Badwaik2019|3D Printed Organs: The Future of Regenerative Medicine.
    De Maria et al.2015|Indirect rapid prototyping for tissue engineering
    US20090186408A1|2009-07-23|Biocompatible bilayer porous matrix and preparation thereof
    Huang et al.2017|Recent advances in cell-laden 3D bioprinting: materials, technologies and applications
    Ouyang2019|3D Bioprinting and Bioink: Background
    FR2927632A1|2009-08-21|CORNEA AND MUQUEUSE RECONSTRUCTED.
    Skardal2018|Principles and applications of bioprinting
    Willson et al.2021|Bioprinting Au Natural: The Biologics of Bioinks
    WO2016059339A1|2016-04-21|Method for producing three-dimensional structures by moulding for tissue engineering
    同族专利:
    公开号 | 公开日
    KR20180099843A|2018-09-05|
    EP3397751A1|2018-11-07|
    FR3046421B1|2021-04-02|
    CN108699517A|2018-10-23|
    US20190002836A1|2019-01-03|
    JP2019500904A|2019-01-17|
    FR3046420A1|2017-07-07|
    WO2017115056A1|2017-07-06|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE10018987A1|2000-04-17|2001-10-31|Envision Technologies Gmbh|Device and method for producing three-dimensional objects|
    CN101219240B|2008-01-18|2010-11-10|清华大学|Production method for living body tissue with channel|
    JP5472844B2|2008-03-03|2014-04-16|国立大学法人富山大学|Method for producing gel|
    JP2012235921A|2011-05-12|2012-12-06|Shiseido Co Ltd|Method for manufacturing three-dimensional skin model|EP3912652A1|2014-12-18|2021-11-24|Cellink AB|Bacterial cellulose nanofibrillar bioink for 3d bioprinting for cell culturing, tissue engineering and regenerative medicine applications|
    JP6782241B2|2015-01-12|2020-11-11|ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ|Multi-layer skin replacement products, and how to make and use them|
    WO2017210663A1|2016-06-03|2017-12-07|Paul Gatenholm|Preparation and applications of rgd conjugated polysaccharide bioinks with or without fibrin for 3d bioprinting of human skin with novel printing head for use as model for testing cosmetics and for transplantation|
    WO2020077118A1|2018-10-10|2020-04-16|Cellink Ab|Double network bioinks|
    FR3091821B1|2019-01-23|2021-01-22|Microfactory|BODY TISSUE SUBSTITUTE|
    EP3967750A1|2019-04-01|2022-03-16|Toppan Inc.|Three-dimensional tissue construct and method for producing same, and method for producing cell-containing composition|
    KR102220365B1|2019-10-25|2021-02-24|울산과학기술원|A manufacturing method for composite tissue using bio-ink based 3D printing|
    WO2021101983A1|2019-11-18|2021-05-27|The Regents Of The University Of California|Tough tissue sealants and the use thereof|
    KR20210105252A|2020-02-18|2021-08-26|주식회사 메디팹|Development of dermal layer with shrinkage control, and preparation of artificial skin with uniform performance|
    CN111588908B|2020-03-11|2021-08-06|南京市第一医院|Biological 3d printed active biofilm for improving AMIC technology cartilage repair and preparation method thereof|
    CN112251352A|2020-09-29|2021-01-22|中国肉类食品综合研究中心|Special culture device for 3D biological tissue and preparation method of blocky cultured meat|
    法律状态:
    2017-03-24| PLFP| Fee payment|Year of fee payment: 2 |
    2017-07-07| PLSC| Publication of the preliminary search report|Effective date: 20170707 |
    2018-03-20| PLFP| Fee payment|Year of fee payment: 3 |
    2020-03-16| PLFP| Fee payment|Year of fee payment: 5 |
    2021-03-24| PLFP| Fee payment|Year of fee payment: 6 |
    2022-02-11| PLFP| Fee payment|Year of fee payment: 7 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1563461A|FR3046420A1|2015-12-30|2015-12-30|PROCESS FOR MANUFACTURING SKIN SUBSTITUTES BY ADDITIVE DEPOSITION|KR1020187022041A| KR20180099843A|2015-12-30|2016-12-29|Manufacturing method of body substitute by addition deposition|
    US16/064,322| US20190002836A1|2015-12-30|2016-12-29|Method for Manufacturing Body Substitutes by Additive Deposition|
    JP2018553319A| JP2019500904A|2015-12-30|2016-12-29|Method for producing body substitutes by additive deposition|
    CN201680082969.5A| CN108699517A|2015-12-30|2016-12-29|Pass through the method for addition deposit manufacture body substitute|
    EP16831829.3A| EP3397751A1|2015-12-30|2016-12-29|Method for manufacturing body substitutes by additive deposition|
    PCT/FR2016/053683| WO2017115056A1|2015-12-30|2016-12-29|Method for manufacturing body substitutes by additive deposition|
    [返回顶部]